Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose crossover PK/PD comparison of SAR341402 vs NovoRapid in healthy Japanese males
jRCT2080225284Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin aspart in diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoints: Pharmacokinetic exposure of SAR341402 vs NovoRapid and Glucodynamic activity of SAR341402 vs NovoRapid. Started Jul 2020; status: completed.
02
Drugs
insulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080225284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225284.